AlphaCrest Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

AlphaCrest Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14,359	Closed	-$889K	–	1250
2022 Q3	$889K	Sell	14,359 -127,857	-90%	-$8.93M	0.05%	687
2022 Q2	$11.3M	Buy	142,216 +100,584	+242%	+$9.53M	0.55%	9
2022 Q1	$4.38M	Sell	41,632 -14,474	-26%	-$1.41M	0.24%	62
2021 Q4	$6.05M	Buy	56,106 +43,949	+362%	+$4.79M	0.22%	70
2021 Q3	$1.33M	Sell	12,157 -806	-6%	-$83.7K	0.07%	487
2021 Q2	$1.21M	Sell	12,963 -4,689	-27%	-$432K	0.05%	569
2021 Q1	$1.63M	Buy	17,652 +1,959	+12%	+$165K	0.09%	332
2020 Q4	$1.15M	Buy	+15,693	New	+$1.17M	0.1%	272
2020 Q2	–	Sell	-22,391	Closed	-$663K	–	1207
2020 Q1	$663K	Buy	+22,391	New	+$758K	0.08%	446
2019 Q3	–	Sell	-11,351	Closed	-$273K	–	1391
2019 Q2	$273K	Buy	+11,351	New	+$288K	0.02%	891

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AlphaCrest Capital Management's HZNP Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 14,359 shares — an estimated $889K sold.

AlphaCrest Capital Management first reported a position in HZNP in Q2 2019 and held it in 10 quarters. The position peaked at $11.3M in Q2 2022. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

AlphaCrest Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 14,359 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $889K.
AlphaCrest Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2019 and held it in 10 quarters.
AlphaCrest Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $11.3M in Q2 2022.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.